Moderna's stock surged 14% to a 52-week high following an FDA advisory panel's unanimous endorsement of its flu vaccine for adults 50 and older, a key step before the August 2026 approval date. The rally also reflects optimism from Moderna's recent Science Day highlighting its expansion into oncology and autoimmune diseases, alongside strong Q1 revenue growth of 264% year-over-year. Despite the surge, analysts remain cautious with a consensus price target below current levels and insider selling noted. Investors will watch the upcoming FDA decision and Phase 3 trial results for further direction.
ResearchAndMarkets.com released a comprehensive report covering over 1,350 precision medicine collaboration and licensing deals from 2019 to 2026. The report offers detailed insights into deal structures, financial terms, and partnership strategies, ...
The global influenza vaccine market, valued at $8.96 billion in 2024, is projected to reach $13.32 billion by 2030 with a 7% annual growth rate. Growth is fueled by rising public health awareness, an expanding elderly population, government immunizat...
Moderna stock, once soaring near $497 during the pandemic, now trades around $55.12 but shows a historically bullish trendline signal that has preceded an 82% chance of gains averaging 68% over the next month. Despite a recent 35% pullback from a Jul...
The U.S. FDA has approved Moderna's mRNA-based flu vaccine, mFLUSIVA, for adults aged 50 and older, marking the first mRNA flu shot authorized in the country. Clinical trials showed it to be 26.6% more effective than traditional flu vaccines. The vac...
